Market capitalization | $1.41b |
Enterprise Value | $1.03b |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 16.80 |
P/S ratio (TTM) P/S ratio | 23.09 |
P/B ratio (TTM) P/B ratio | 3.73 |
Revenue growth (TTM) Revenue growth | 11.90% |
Revenue (TTM) Revenue | $61.10m |
As a Free StocksGuide user, you can view scores for all 6,908 stocks worldwide.
8 Analysts have issued a Ocular Therapeutix Inc forecast:
8 Analysts have issued a Ocular Therapeutix Inc forecast:
Dec '23 |
+/-
%
|
||
Revenue | 58 58 |
13%
13%
|
|
Gross Profit | 53 53 |
13%
13%
|
|
EBITDA | -79 -79 |
4%
4%
|
EBIT (Operating Income) EBIT | -82 -82 |
5%
5%
|
Net Profit | -81 -81 |
14%
14%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline includes Dextenza, OTX-TP, and OTX-TIC. The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA.
Head office | United States |
CEO | Pravin Dugel |
Employees | 267 |
Founded | 2006 |
Website | www.ocutx.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.